As chairman of the Pricing, Reimbursement, and Access Steering Committee for Lilly USA and as the relevant profit and loss business unit leader for the biomedicines business unit for the United States, I approved pricing recommendations for this medicine.
Wyden cites Azar's role in pricing strategies for a specific drug during his tenure at Lilly USA.
Share
More from Ron Wyden
Pete Hegseth has made no secret of his contempt for women and transgender servicemembers.
Our state’s world-renowned wood products industry only gets stronger with federal investments like these that sharpen its cutting edge, keep generating jobs and lessen the dangers from wildfires.
Taxpayers cannot keep writing blank checks for a Department of Defense that repeatedly fails to account for trillions of dollars in assets.
I’m heading home this weekend to meet with Oregonians fearing in real time for their lives and livelihoods because of wildfires threatening communities and spreading smoke statewide.
Other voices in this conversation
